Abstract
Aim: This study aimed to explore the antiangiogenic mechanism of quinacrine-gold hybrid nanoparticle (QAuNP) and near-infrared (NIR) radiation in patient-derived primary breast cancer stem cells. Materials & methods: Various cell-based in ovo angiogenesis and in vivo patient-derived xenograft mouse systems were used as models for the study. Results: The experimental results showed that QAuNP + NIR treatment deregulated the HSP-70/TGF-β physical interaction in primary breast cancer stem cells. Reduced TGF-β secretion in the tumor microenvironment inhibited angiogenesis activation in endothelial cells by deregulating the TGF-β-mediated PI3K/AKT/mTOR cascade. Conclusion: This study revealed that QAuNP + NIR irradiation downregulated HSP-70 expression, inhibited the HSP-70/TGF-β interaction, reduced the secretion of TGF-β in the tumor microenvironment and ultimately inhibited TGF-β-mediated angiogenesis.
Graphical abstract
Plain language summary
This study discovered that the formation of blood vessels in breast cancer is significantly reduced when hybrid nanoparticles and infrared laser therapy are used to treat breast cancer stem cells. The secretory cytokines in the tumor microenvironment primarily responsible for developing blood vessels in the tumor are dramatically reduced by treatment. As a result, the tumor's blood vessel growth is reduced, making it difficult for the cancer cells to get the nutrients and oxygen they need to survive.
Tweetable abstract
Near-infrared radiation enhances the antiangiogenic potentiality of quinacrine-gold hybrid nanoparticles in patient-derived breast cancer stem cells via deregulation of the HSP-70/TGF-β axis.
Papers of special note have been highlighted as: • of interest
References
- 1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
- 2. . Angiogenesis in breast cancer progression, diagnosis, and treatment. J. Cancer 11(15), 4474–4494 (2020). • Highlights the mechanism of angiogenesis in diseases and its role in the progression of malignancy in breast cancer.
- 3. . Tumor angiogenesis: current challenges and therapeutic opportunities. Cancer Treat. Res. Commun. 28, 100422 (2021). • Provides an overview of concepts of tumor angiogenesis and several important angiogenic factors as well as focuses on the role of antiangiogenesis strategies in cancer treatment.
- 4. . Angiogenesis in cancer. Vasc. Health Risk Manag. 2(3), 213 (2006).
- 5. . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309–322 (2012).
- 6. . Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch. Pharm. Res. 45(6), 1–16 (2022).
- 7. . Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J. Hematol. Oncol. 13(1), 1–22 (2020).
- 8. . Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 25(1), 1–18 (2018).
- 9. Cancer stem cells and angiogenesis. Int. J. Dev. Biol. 55(4–5), 477–482 (2011).
- 10. Transforming growth factor-beta (TGF-β) signaling in cancer – a betrayal within. Front. Pharmacol. 13 (2022). • Findings showed the dual role of TGF-β under different cellular conditions and its crosstalk with other signaling pathways in modulating cell fate and angiogenesis.
- 11. . TGF-β signaling: a complex role in tumorigenesis. Mol. Med. Rep. 17(1), 699–704 (2018).
- 12. Role of matrix metalloproteinases in angiogenesis and cancer. Front. Oncol. 9, 1370 (2019).
- 13. . Side effects of anti-angiogenic drugs. Thromb. Res. 129, S50–S53 (2012).
- 14. Nanomaterials for antiangiogenic therapies for cancer: a promising tool for personalized medicine. Int. J. Mol. Sci. 22(4), 1631 (2021).
- 15. CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Sci. Rep. 7(1), 1–12 (2017).
- 16. HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway. Sci. Rep. 7(1), 1–14 (2017). • First study that showed VEGF independent angiogenesis.
- 17. NIR irradiation enhances the apoptotic potentiality of quinacrine-gold hybrid nanoparticles by modulation of HSP-70 in oral cancer stem cells. Nanomedicine 40, 102502 (2022).
- 18. . Anti-cancer stem cells potentiality of an anti-malarial agent quinacrine: an old wine in a new bottle. Anti-Cancer Agents Med. Chem. 21(4), 416–427 (2021).
- 19. . Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells. Eur. J. Pharmacol. 883, 173308 (2020).
- 20. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8(23), 3960–3970 (2009).
- 21. . Photothermal therapy: a new approach to eradicate cancer. Curr. Nanosci. 18(1), 31–47 (2022).
- 22. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 11(9), 3530–3534 (2005).
- 23. Quinacrine based gold hybrid nanoparticles caused apoptosis through modulating replication fork in oral cancer stem cells. Mol. Pharm. 17(7), 2463–2472 (2020).
- 24. . Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis. Vascul. Pharmacol. 140, 106865 (2021).
- 25. . PARP inhibitor veliparib (ABT-888) enhances the anti-angiogenic potentiality of curcumin through deregulation of NECTIN-4 in oral cancer: role of nitric oxide (NO). Cell Signal. 80, 109902 (2021).
- 26. . Nano formulated resveratrol inhibits metastasis and angiogenesis by reducing inflammatory cytokines in oral cancer cells by targeting tumor associated macrophages. J. Nutr. Biochem. 92, 108624 (2021).
- 27. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4. Int. J. Biochem. Cell Biol. 102, 151–160 (2018).
- 28. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64(11), 937–946 (2011).
- 29. . CD133 in breast cancer cells: more than a stem cell marker. J. Oncol. 2019, 1–8 (2019).
- 30. . Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 1 –19 (2014).
- 31. . The tumor microenvironment. Curr. Biol. 30(16), R921–R925 (2020).
- 32. The role of microenvironment in tumor angiogenesis. J. Exp. Clin. Cancer Res. 39(1), 1–19 (2020).